Get the Stockscreener App
1.845
1.34%
-0.025
Pre-market:
1.84
-0.005
-0.27%
Esperion Therapeutics Inc stock is traded at $1.845, with a volume of 4.17M.
It is down -1.34% in the last 24 hours and up +55.04% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$1.87
Open:
$1.87
24h Volume:
4.17M
Relative Volume:
0.85
Market Cap:
$365.68M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-0.8703
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
+23.83%
1M Performance:
+55.04%
6M Performance:
+3.07%
1Y Performance:
-8.66%
1-Day Range:
$1.78
$1.87
1-Week Range:
$1.59
$1.9693
52-Week Range:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.845 | 370.63M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
149.02 | 65.30B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 45.60B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.42 | 18.78B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
300.43 | 13.64B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Esperion Delays Q2 2025 Financial Report Filing - TipRanks
Published on: 2025-08-10 18:32:11 - beatles.ru
Esperion Therapeutics Inc. At Decision Level — Rebound or ResistanceExpert Verified Stock Trade Ideas Backed by Data - beatles.ru
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises - MSN
Published on: 2025-08-08 10:01:24 - beatles.ru
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) for New Employees - AInvest
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Esperion Grants 73,500 RSUs with 4-Year Vesting Schedule to Attract Top Talent - Stock Titan
Esperion rises after revenue beat, Q1 profitability expectation - MSN
Esperion Therapeutics’ Earnings Call Highlights Growth - The Globe and Mail
Esperion (ESPR) Q2 Revenue Jumps 12% - AOL.com
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript - Insider Monkey
Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues - MSN
Esperion Therapeutics: Q2 Earnings Snapshot - New Haven Register
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ... By GuruFocus - Investing.com Canada
Esperion Therapeutics Reports Strong Q2 2025 Growth - TipRanks
Esperion Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Will Esperion Therapeutics Stock Surge Sustain? - StocksToTrade
Esperion's Q2 2025 Earnings Call: Unpacking Key Contradictions in Market Access, Growth Strategies, and Revenue Projections - AInvest
Transcript : Esperion Therapeutics, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Esperion Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ESPR) - Seeking Alpha
Earnings call transcript: Esperion Therapeutics Q2 2025 beats forecasts, stock rises - Investing.com Canada
Earnings call transcript: Esperion Therapeutics Q2 2025 beats forecasts, stock rises By Investing.com - Investing.com South Africa
Esperion Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Esperion Therapeutics Q2 Earnings: Narrower Loss and Revenue BeatNews and Statistics - IndexBox
Esperion Reports 12% Revenue Growth in Q2 2025 with Significant Increases in U.S. Product Sales and Settlements with ANDA Filers - Quiver Quantitative
Esperion Therapeutics Q2 revenue up 12%, operating profit beats estimates - MarketScreener
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Esperion Reports Record 42% Revenue Growth, Secures Patent Protection Until 2040 in Breakthrough Quarter - Stock Titan
How many analysts rate Esperion Therapeutics Inc. as a “Buy”Discover top stock picks for aggressive growth - Jammu Links News
Is Esperion Therapeutics Inc. a good long term investmentAchieve rapid financial growth with expert help - Jammu Links News
What are the latest earnings results for Esperion Therapeutics Inc.Free Market Dynamics Reports - Jammu Links News
What are the technical indicators suggesting about Esperion Therapeutics Inc.Strong return on investment - Jammu Links News
Should I hold or sell Esperion Therapeutics Inc. stock in 2025Rapid wealth multiplication - Jammu Links News
Is Esperion Therapeutics Inc. stock overvalued or undervaluedAchieve breakthrough performance with smart picks - Jammu Links News
Is Esperion Therapeutics Inc. a growth stock or a value stockFree Stock Chart Pattern Guide - Jammu Links News
What institutional investors are buying Esperion Therapeutics Inc. stockBuild a diversified portfolio for risk management - Jammu Links News
What is the dividend policy of Esperion Therapeutics Inc. stockInvest smarter with data-backed trading alerts - Jammu Links News
Esperion Therapeutics Inc. Stock Analysis and ForecastCapitalize on stocks with high profit margins - Jammu Links News
How strong is Esperion Therapeutics Inc. company’s balance sheetUnlock powerful portfolio management tools - Jammu Links News
What are Esperion Therapeutics Inc. company’s key revenue driversExceptional trading performance - Jammu Links News
How does Esperion Therapeutics Inc. compare to its industry peersFree Stock Outlook That Work - Jammu Links News
Esperion Therapeutics soars amid vague takeover speculation - MSN
Esperion Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
2.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):